Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of ordinary shares via dividend re-investment |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Volume | 55 shares |
| Price | £16.5875 per share |
| Transaction Date | July 14, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single acquisition event by Mr. J P Witty, identified as a PCA of Sir Andrew Witty (CEO).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a routine disclosure of a dividend re-investment transaction.
Key Facts for Investor Verification
- The transaction involved the acquisition of 55 ordinary shares by Mr. J P Witty.
- The shares were acquired through the re-investment of dividends paid on July 14, 2016.
- The transaction price was £16.5875 per share.
- The filing does not contain financial results or strategic updates for the company.